A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 29(2020), 2 vom: 14. Feb., Seite 103-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tilg, Herbert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Canakinumab |
|---|
| Anmerkungen: |
Date Completed 05.03.2020 Date Revised 05.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2020.1681397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30221786X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30221786X | ||
| 003 | DE-627 | ||
| 005 | 20231225110245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2020.1681397 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM30221786X | ||
| 035 | |a (NLM)31615278 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tilg, Herbert |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2020 | ||
| 500 | |a Date Revised 05.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Canakinumab | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a metabolic inflammation | |
| 650 | 4 | |a nonalcoholic fatty liver disease | |
| 650 | 7 | |a Interleukin-1alpha |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 700 | 1 | |a Effenberger, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Adolph, Timon E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 29(2020), 2 vom: 14. Feb., Seite 103-106 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2020 |g number:2 |g day:14 |g month:02 |g pages:103-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2020.1681397 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2020 |e 2 |b 14 |c 02 |h 103-106 | ||